Incruse Ellipta (Umeclidinium Bromide)

Umeclidinium bromide blocks muscarinic M3 receptors on airway smooth muscle, preventing acetylcholine‑induced constriction. This selective antagonism relaxes the bronchial muscles, leading to sustained bronchodilation and improved airflow throughout the day.

The prescribed dose of Incruse Ellipta is determined by the treating physician based on the patient’s clinical condition and response. The medication is delivered via a pre‑metered inhaler, typically as one inhalation once daily.

The safety of Incruse Ellipta in pregnancy and lactation has not been definitively established. Healthcare providers should weigh the potential benefits against any possible risks and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Incruse Ellipta belongs to the long‑acting muscarinic antagonist (LAMA) class, offering once‑daily dosing and a favorable safety profile. Compared with short‑acting bronchodilators, it provides more consistent airway protection, and versus some combination inhalers, it delivers a single‑agent approach that may simplify therapy for patients who only need a LAMA.

Store the inhaler at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight and extreme heat to maintain device integrity and drug potency.

Incruse Ellipta is used via a dry‑powder inhaler. The patient opens the device, exhales fully away from the inhaler, places the mouthpiece in the mouth, and inhales forcefully and deeply in a single breath. The inhaler is then closed to protect the dose.

Serious risks include paradoxical bronchospasm, severe allergic reactions such as anaphylaxis, and rare cardiac events like chest pain or palpitations. Patients should seek immediate medical attention if they experience sudden worsening of breathing, rash, swelling, or chest discomfort.

Incruse Ellipta should be avoided in individuals with a known hypersensitivity to umeclidinium bromide or any inhaler components. It is also not suitable as a rescue medication for acute bronchospasm and should be used with caution in patients with significant cardiovascular disease.